Universe Pharmaceuticals Book Value Per Share Growth & History (UPC)
Universe Pharmaceuticals's book value per share was $99.64 for fiscal 2025.
View full Universe Pharmaceuticals company overviewUniverse Pharmaceuticals annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | $99.64 | -$1,061,069.70 | −99.99% |
| 2024 | 2024-09-30 | $1,061,169.33 | $1,053,453.43 | +13653.01% |
| 2023 | 2023-09-30 | $7,715.90 | $7,706.16 | +79067.10% |
| 2022 | 2022-09-30 | $9.75 | -$3.22 | −24.82% |
| 2021 | 2021-09-30 | $12.96 | $5.16 | +66.17% |
| 2020 | 2020-09-30 | $7.80 | $3.16 | +67.98% |
| 2019 | 2019-09-30 | $4.64 | — | — |
Universe Pharmaceuticals quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-03-31 | $85.89 | -$12.07 | −12.32% |
| Q4 2025 | 2025-09-30 | $99.64 | -$1,061,069.70 | −99.99% |
| Q2 2025 | 2025-03-31 | $97.96 | $90.63 | +1235.48% |
| Q4 2024 | 2024-09-30 | $1,061,169.33 | $1,053,453.43 | +13653.01% |
| Q2 2024 | 2024-03-31 | $7.34 | -$5.67 | −43.58% |
| Q4 2023 | 2023-09-30 | $7,715.90 | $7,706.16 | +79067.10% |
| Q2 2023 | 2023-03-31 | $13.00 | -$3.87 | −22.94% |
| Q4 2022 | 2022-09-30 | $9.75 | -$3.22 | −24.82% |
| Q2 2022 | 2022-03-31 | $16.87 | — | — |
| Q4 2021 | 2021-09-30 | $12.96 | — | — |
Universe Pharmaceuticals book value per share trends
Over the last five fiscal years, Universe Pharmaceuticals's book value per share increased from $7.80 to $99.64, a change of $91.84. The latest reported quarter, Q2 2026, shows $85.89.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Universe Pharmaceuticals source filings ↗